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AbsTrACT
background little is known about the impact of 
exacerbations on cOPD progression or whether inhaled 
corticosteroid (ics) use and blood eosinophil count 
(Bec) affect progression. We aimed to assess this in a 
prospective observational study.
Methods The study population included patients 
with mild to moderate cOPD, aged ≥35 years, with a 
smoking history, who were followed up for ≥3 years 
from first to last spirometry recording using two large 
UK electronic medical record databases: clinical Practice 
research Datalink (cPrD) and Optimum Patient care 
research Database (OPcrD). Multilevel mixed- effects 
linear regression models were used to determine the 
relationship between annual exacerbation rate following 
initiation of therapy (ics vs non- ics) and FeV1 decline. 
effect modification by blood eosinophils was studied 
through interaction terms.
results Of 12178 patients included (mean age 66 
years; 48% female), 8981 (74%) received ics. in patients 
with Bec ≥350 cells/µl not on ics, each exacerbation 
was associated with subsequent acceleration of 
FeV1 decline of 19.4 ml/year (95% ci 12.0 to 26.7, 
p<0.0001). This excess decline was reduced by 15.1 ml/
year (6.6 to 23.6) to 4.3 ml/year (1.9 to 6.7, p<0.0001) 
in those with Bec ≥350 cells/µl treated with ics.
Conclusion exacerbations are associated with a more 
rapid loss of lung function among cOPD patients with 
elevated blood eosinophils, defined as ≥350 cells/µl, 
not treated with ics. More aggressive prevention of 
exacerbations using ics in such patients may prevent 
excess loss of lung function.
InTroduCTIon
COPD is a progressive respiratory condition char-
acterised by non- reversible airflow limitation.1 In 
approximately half of patients, COPD results from 
accelerated lung function decline following normal 
lung growth and development during childhood 
and adolescence.2 3 Lung function decline is most 
accelerated in mild to moderate disease and can 
occur prior to a clinical diagnosis of COPD. For 
example, Tantucci et al reviewed spirometric data 
from patients with COPD in the placebo arms of 
clinical trials and found that lung function decline 
was most accelerated in the initial phases of COPD 
(GOLD stage II).4 A recent study by Bhatt et al 
confirmed that in a population of current and former 
smokers, the rate of FEV1 decline was greatest in 
mild COPD.5 Thus, evaluating individuals at an 
earlier stage before they have lost much of their 
lung function is important in assessing treatment 
effectiveness.
Good adherence to maintenance therapy from 
the early stages of disease onwards may slow disease 
progression. Treatment with inhaled corticoste-
roids (ICS) may prevent structural changes in the 
lung associated with COPD exacerbations.6 It has 
been demonstrated that patients who suffer recur-
rent exacerbations have increased concentrations 
of inflammatory markers in their sputum.7 This 
suggests that the presence of persistent inflamma-
tion may underlie COPD disease progression.8 9 
However, recent clinical trials have demonstrated 
only modest effects of maintenance inhalation 
therapy on reduction of lung function decline in 
patients with COPD.10 11 Thus, questions remain as 
to whether inflammation or other factors are linked 
to COPD disease progression and whether these 
can be modified by treatment.
Acute exacerbations have been associated with 
accelerated lung function decline, particularly 
Key messages
What is the key question?
 ► We aimed to assess whether chronic obstructive 
pulmonary disease (COPD) exacerbations 
occurring under maintenance therapy, earlier 
on in the life cycle of COPD, are associated with 
accelerated subsequent lung function decline 
and whether the blood eosinophil count (BEC) 
is a biomarker for risk stratification.
What is the bottom line?
 ► This study provides novel and important 
evidence that exacerbations occurring in 
patients with mild to moderate COPD who 
demonstrate elevated blood eosinophils are 
associated with rapid lung function loss, and 
that receiving inhaled corticosteroid (ICS) in 
these patients is associated with significant 
mitigation of lung function decline.
Why read on?
 ► This study addresses the importance of 
recognising the need for ICS treatment to 
prevent rapid lung function loss associated with 
exacerbations in patients who demonstrate 
high BECs in daily clinical practice.
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Figure 1 Study design. BEC, blood eosinophil count; FU, follow- up; 
ICS, inhaled corticosteroid.
Table 1 Inclusion and exclusion criteria for study population
Criteria
Inclusion  ► Diagnostic Read code for COPD
   ► Age ≥35 years
   ► Spirometry recorded between 3 months before and 12 months after 
the first COPD diagnostic code (index date)
   ► Evidence of obstruction ever recorded (FEV1/FVC<0.7)
   ► Mild to moderate airflow limitation (FEV1 % predicted ≥50% and 
≤90% at index date)
   ► ≥1 year of up- to- standard* medical records prior to index date to 
enable baseline characterisation
   ► History of smoking tobacco prior to first COPD diagnosis or at first 
recording after diagnosis
   ► Height at adult age (≥21 years) and weight recorded within 5 years 
of index date
   ► Up- to- standard* follow- up period covering ≥3 years between the 
first and last spirometry records
Exclusion  ► Active asthma at or after the date of first COPD diagnosis, defined 
as ≥1 diagnostic Read code for asthma or ≥1 asthma monitoring or 
review codes recorded, or asthma- COPD overlap syndrome as first 
COPD diagnostic code or recorded during follow- up
   ► Diagnostic code for other chronic lower respiratory conditions ever 
recorded
   ► Severe airflow limitation (FEV1 % predicted <50% at index date) as 
there is limited scope for further FEV1 decline and early intervention 
in these patients
*Up- to- standard data are of continuous high quality and considered suitable for 
research.
in those with mild disease (GOLD stage I).12 13 It is unknown 
whether ICS treatment is effective in preventing this potential 
damage to the lungs associated with exacerbations. Additionally, 
blood eosinophils are known to predict the risk of future events 
and response to ICS in terms of exacerbation prevention and 
improvement in lung function. Patients with a high blood eosin-
ophil count (BEC) were found to be most responsive to treat-
ment with ICS.14–18 It is however unknown whether BECs could 
be a good biomarker to identify patients who would benefit 
from ICS in terms of slowing lung function decline at earlier 
stages of disease development. This has been suggested by a post 
hoc analysis of a small group of clinical trial patients with more 
advanced COPD.19 We aimed to assess whether COPD exacer-
bations occurring under maintenance therapy, earlier on in the 
life cycle of COPD, are associated with accelerated subsequent 
lung function decline and whether the BEC is a biomarker for 
risk stratification.
MeThods
study design and data sources
A prospective observational study was carried out among 
patients with COPD in the UK (figure 1). Primary care data were 
extracted from the Clinical Practice Research Datalink (CPRD; 
http://www. cprd. com/) and Optimum Patient Care Research 
Database (OPCRD; https:// opcrd. co. uk/). Further details of 
these data sources are provided in the online supplementary. 
Clinical data are recorded using Read codes; the codes used for 
COPD were those within the Quality and Outcomes Frame-
work (QOF) and the diagnosis has been validated.20 21 Practices 
who contributed to both CPRD and OPCRD and had ≥60% 
overlap in patient age, gender and index date (defined below) 
were assumed to be the same, and thus patient records from 
the OPCRD dataset for that practice were removed as duplicate 
when the datasets were merged.
study population
This study included patients diagnosed with mild to moderate 
COPD (FEV1 % predicted ≥50% and ≤90%) at age ≥35 years, 
who had a history of tobacco smoking and evidence of obstruc-
tion ever recorded. Patients with active asthma at or after the 
date of the first COPD diagnosis were excluded, as were those 
with <3 years of spirometry follow- up. Further details regarding 
inclusion and exclusion criteria are presented in table 1. All Read 
code lists are available on request.
data collection and study variables
The index date was the date of the FEV1 recording closest to 
3 months before to 12 months after the first COPD diagnosis. 
Data on demographics, clinical characteristics and comorbidi-
ties were collected at baseline (1 year prior to index date) for 
included patients. The primary outcome was decline in FEV1 
(mL/year) during follow- up (from first to last FEV1 recording). 
The exposures of interest (see table 2 for detailed definitions 
and categorisation) included the highest level of maintenance 
therapy, annual exacerbation rates, BEC and adherence to main-
tenance therapy.
data analyses
All analyses were carried out in Stata V.14.2 (StataCorp, College 
Station, Texas, USA). Summary descriptive statistics were 
computed using proportions for categorical variables and means 
(with SD) and medians (with IQR) for continuous variables. 
The standardised mean difference (SMD) was used to quantify 
differences in baseline variables between patients who initiated 
maintenance therapy with or without ICS and subpopulations 
of patients who had BEC available (<50, 50–349, ≥350 cells/
µL). An SMD of <10% indicated sufficient balance between the 
groups. Blood eosinophil values were mostly recorded as 109/L 
to one decimal place in electronic medical records. A value of 
0.3×109/L could fall anywhere between 250 and 349 cells/µL. 
Thus, it is unknown whether such a value is below or above 
the recommended cut- off point of 300 cells/µL. Cut- off points 
of 250, 350 and 450 cells/µL were therefore considered in the 
analyses, with 350 as the primary cut- off point.
A multilevel ‘random- slope/random- intercept’ model was 
used to model FEV1 change over time. Fixed effects with 95% CI 
were estimated for the association between annual exacerbation 
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Table 2 Variable definitions and categorisation
Variables definitions
Highest level of maintenance therapy
(ICS, non- ICS)
 ► Therapy prescribed for at least 1 year (as separate overlapping prescriptions or as fixed dose combinations) from 1 year 
prior to the first FEV1 recording to the last FEV1 recording
   ► Ordered from lowest to highest as long- acting bronchodilator only, ICS monotherapy, ICS+LABD, LAMA+LABA and triple 
therapy (ICS+LAMA+ LABA), and then grouped into ICS or non- ICS
Annual exacerbation rate  ► Exacerbations occurring after initiation of the highest level of maintenance therapy until the last FEV1 recording were 
counted and divided by the total time of follow- up (days/365)
   ► COPD exacerbation was defined as occurrence of any of the following events: respiratory- related hospital attendance/
admission; respiratory- related emergency room attendance; prescription of acute OCS course; and/or antibiotics 
prescribed with evidence of lower respiratory consultation on the same day
   ► Events occurring within 14 days of each other were considered the same exacerbation
Blood eosinophil count
(<50, 50–349,≥350 cells/µL)
 ► Recorded within a maximum 2 year period before or after date of therapy initiation
   ► Counts measured within 14 days following an OCS prescription were excluded
   ► Cut- off values 250 and 450 cells/µL also considered
Overall adherence to maintenance therapy
(<50%, 50%–79%, 80%–100%, >100%)
 ► Calculated as the ratio of total time covered by prescriptions of maintenance inhalers (all types, not only highest level) 
and the total duration of follow- up from maintenance therapy initiation to the last FEV1 recording
   ► Time covered by one inhaler assumed to be 30 days for all inhalers, except for ICS single inhalers for which 50 days was 
assumed
ICS, inhaled corticosteroid; LABA, long- acting beta- agonists; LABD, long- acting bronchodilator; LAMA, long- acting muscarinic antagonist; OCS, oral corticosteroids.
Figure 2 Flow diagram of patient selection. CPRD, Clinical Practice 
Research Datalink; OPCRD, Optimum Patient Care Research Database.
rate after initiation of the highest maintenance therapy (contin-
uous variable) and FEV1 decline, stratified by therapy level 
during follow- up. The intercept of the model was the baseline 
FEV1 at first diagnosis. An interaction term of follow- up time 
with the annual exacerbation rate represented the association 
of exposure with slope of FEV1 decline. Random effects were 
included, allowing each patient’s change in lung function over 
time to be scattered around the population average trajectory, 
assuming that the errors were independent and normally distrib-
uted. The model also included sex, age, height, weight and 
smoking status as covariates, including an interaction term with 
time, to adjust for potential confounding by other well- known 
risk factors of lung function decline. All recorded FEV1 values, 
including values recorded prior to index date, were analysed 
as the outcome. Differences in associations between groups, 
defined by BEC, were statistically tested through interaction 
terms. CIs of reported differences in associations between both 
strata of patients with and without ICS therapy were estimated 
from a model including interaction terms, stratified by eosino-
phil count. Marginal FEV1 decline with 95% CIs were visual-
ised at mean exacerbation rates of 0–3, while covariates were 
held at their mean value from models stratified by therapy, 
including interaction terms for blood eosinophil categories. 
Overall adherence to maintenance therapy (in general), calcu-
lated as the percentage of total follow- up time after initiation 
of maintenance therapy that was covered by inhaler prescrip-
tions, was added to the model to assess its association with lung 
function decline (table 2). The following two sensitivity analyses 
were conducted: (1) excluding all patients ever diagnosed with 
asthma due to potential misclassification between COPD and 
asthma, and (2) including only patients with at least five FEV1 
measurements to assess the impact of less accurate estimates of 
lung function decline in patients with few measurements.
role of funding source
The funders of the study participated in the study design. All 
authors, including those employed by the funders of the study, 
participated in the data interpretation and writing of the report. 
All authors had full access to study results and had final respon-
sibility for the decision to submit for publication.
resulTs
study population
A total of 25560 patients with at least 3 years of follow- up 
(median 6.2; IQR 4.5–8.5) after the first FEV1 recording were 
included in the study (figure 2). Patients had a median of six (IQR 
4–8) FEV1 recordings; 72% of patients had at least five record-
ings, while only 2.4% had two recordings available. The median 
index year for these patients was 2008 (IQR 2006–2010).
Among patients who initiated maintenance therapy 
(n=19439), 51% achieved the highest level of therapy within 
1 year after baseline spirometry (median number of days: 336 
(IQR 0–1089)). The median duration of spirometry follow- up 
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after initiation of the highest level of therapy was 4 years (1442 
days (IQR 978–2088)) and was less than 1 year in only 1% of 
patients (minimum 177 days). Three- quarters of those who initi-
ated maintenance therapy (n=14572) were treated with ICS and 
4867 (25.0%) without ICS as the highest level of therapy during 
follow- up. Triple therapy (ICS+LAMA+ LABA) was prescribed 
to 6816 (35%) patients.
Almost 63% of those who initiated maintenance therapy 
(12178/19439) had BECs available. Half of the BECs were 
recorded within 6 months of highest therapy initiation and 
82% within 1 year (median=129 days; IQR=44–291). BEC 
was available for 8981 (62%) patients who initiated ICS and 
3197 (66%) patients who initiated non- ICS containing therapy 
as the highest level of maintenance therapy. There was a similar 
proportion of patients with eosinopenia (<50 cells/µL) in both 
groups (304 (3.4%) in ICS vs 110 (3.4%) in non- ICS). A higher 
proportion of patients in the ICS- containing therapy group had 
a high BEC compared with patients in the non- ICS containing 
therapy group. In the ICS group, 20.6% (n=1849) and 11.1% 
(n=993) had BEC of ≥350 and ≥450 cells/µL, respectively, 
compared with 17.0% (n=543) and 7.6% (n=243) in the non- 
ICS group.
Patient characteristics
Characteristics of patients treated with or without ICS as the 
highest level of therapy during follow- up are presented in 
table 3. Patients treated with ICS had longer follow- up, higher 
modified Medical Research Council (mMRC) scores and more 
severe disease (GOLD group). They also experienced more exac-
erbations in the year prior to the first COPD diagnosis, the year 
prior to initiation of the highest therapy,and during follow- up 
after initiation. A higher proportion of patients on ICS had a 
previous diagnosis of asthma. The presence of other comorbidi-
ties was similar between groups (SMD<10%; see online supple-
mentary table S1 in online supplementary).
Of 12178 patients with BEC recorded closest to initiation of 
the highest level of maintenance therapy, 414 (3.4%) had <50, 
9372 (77.0%) had 50–349 and 2392 (19.6%) had ≥350 cells/µL. 
Demographic and clinical characteristics for these patient groups 
are presented in table 4. Patients with high BECs (≥350 cells/µL) 
were more frequently male, more often had a previous diagnosis 
of nasal polyps and had higher rates of exacerbations. Patients 
with eosinopenia (<50 cells/µL) had a relatively low BMI, more 
often a diagnosis of osteoporosis, received more prescriptions 
for oral corticosteroids (OCS), had higher mMRC scores and 
consulted their general practitioner (GP) more frequently 
for reasons other than COPD. Further patient characteristics 
are displayed in online supplementary table S2 in the online 
supplementary.
lung function decline associated with increasing 
exacerbation rates
Patients treated with or without ICS
This analysis included 14572 patients who were treated with 
ICS and 4867 without ICS as the highest level of therapy during 
follow- up. Patients with higher annual rates of exacerbations 
after initiation of ICS- containing therapy had a significantly 
faster FEV1 decline (5.8 mL/year per one unit increase in annual 
exacerbation rate (95% CI 4.9 to 6.6), p<0.0001). This was 
similar for patients on non- ICS containing therapy (5.7 mL/year 
(3.6 to 7.7), p<0.0001; figure 3).
Patients with BEC ≥350 cells/µL, stratified by therapy
Subsequent analyses included 12178 patients with BEC available 
(414 with <50, 9372 with 50–349 and 2392 with ≥350 cells/
µL). The lowest absolute level of lung function decline was 
seen in patients with a BEC ≥350 cells/µL who did not experi-
ence any exacerbation following therapy initiation even though 
they never received an ICS prescription (31.9 mL/year (95% CI 
26.5 to 37.2); figure 4). However, when patients with a BEC 
≥350 cells/µL experienced exacerbations while not treated with 
ICS, a substantial excess decline of 19.4 mL/year (95% CI 12.0 
to 26.7, p<0.0001) with every increase of one exacerbation per 
year was observed (figure 4C). This excess decline associated 
with increasing exacerbation rate was reduced by 15.1 mL/year 
(6.6 to 23.6) to 4.3 mL/year (1.9 to 6.7, p<0.0001) in those 
with a BEC ≥350 cells/µL treated with ICS (figure 4C). Sensi-
tivity analyses including patients with at least five available FEV1 
measurements (n=9276; 7024 ICS, 2252 non- ICS) showed 
similar results; a significant excess FEV1 decline of 16.1 mL/year 
(95% CI 8.0 to 24.1, p<0.0001) was evident with every increase 
of one exacerbation per year in patients with BECs ≥350 cells/
µL who were not treated with ICS (online supplementary figure 
S1).
Patients with BEC 50–349 cells/µL, stratified by therapy
Significant excess lung function decline associated with increasing 
exacerbation rates was not seen in patients with a BEC of 
50–349 cells/µL who did not receive ICS (2.3 mL/year (95% CI 
−0.7 to 5.4), p=0.1370; figure 4B), but was present and signifi-
cantly (p=0.0060) greater for patients who were treated with 
ICS (6.7 mL/year (5.3 to 8.0), p<0.0001; figure 4B).
Patients with BEC <50 cells/µL, stratified by ICS therapy
The association between exacerbation rate and excess decline in 
patients with eosinopenia was not significantly different from 
that observed in patients with a BEC of 50–349 cells/µL (p value 
interaction term=0.5334 for patients on ICS and 0.8100 for 
patients not treated with ICS; figure 4A).
Eosinophil cut-off points of 250 and 450 cells/µL
A lower BEC cut- off point of 250 cells/µL did not result in any 
significant effect modification. Using a higher cut- off point of 
450 cells/µL resulted in significant effect modification by the 
BEC of the association between exacerbations and decline among 
patients treated with ICS, which was not significant (p=0.096) 
when using a cut- off point of 350 cells/µL. The association 
was non- significant for patients treated with ICS with a BEC 
≥450 cells/µL (1.0 mL/year (95% CI −2.5 to 4.5), p=0.5662; 
online supplementary figure S2 in online supplementary). See 
online supplementary tables S3- S6 in the online supplementary 
for details of regression coefficients for the models reported.
exclusion of patients ever diagnosed with asthma
In patients with a BEC ≥350 cells/µL who were never diagnosed 
with asthma and never received prescriptions for ICS, an excess 
decline of 18.8 mL/year (95% CI 11.4 to 26.2, p<0.0001) with 
every increase of one exacerbation per year was also evident (see 
online supplementary figure S3 in online data supplementary).
Adherence
Patients with <50% (low level) adherence who were receiving 
ICS had significantly more decline than patients with 80%–100% 
(good) adherence (difference=5.1 mL/year (95% CI 1.9 to 8.3), 
p=0.0017). In patients not treated with ICS, poor adherence 
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(n=14572) P value sMd
Follow- up after index date, years
  Median (IQR) 5.5 (4.1–7.7) 6.5 (4.7–8.7) <0.0001 30.2
Age (years) at index date
  Mean (SD) 66.0 (9.8) 65.3 (10.0) <0.0001 6.9
Male sex, n (%) 2658 (54.6) 7557 (51.9) 0.0009 5.5
BMI, n (%)
  Underweight 153 (3.1) 430 (3.0) 0.2941 2.2
  Normal weight 1550 (31.8) 4786 (32.8)
  Overweight 1747 (35.9) 5293 (36.3)
  Obese 1417 (29.1) 4063 (27.9)
Baseline smoking status, closest within 5 years, n (%) n=4565 n=13376
  Ex- smoker 2183 (47.8) 6922 (51.7) <0.0001 7.9
Smoking status up to 5 years of follow- up after index date, n (%) n=4561 n=13367
  Sustained quitter 1486 (32.6) 4581 (34.3) <0.0001 6.7
  Intermittent quitter 1494 (32.8) 4655 (34.8)
  Continuous smoker 1581 (34.7) 4131 (30.9)
Asthma diagnosis ever, n (%) 293 (6.0) 2874 (19.7) <0.0001 41.8
Charlson Comorbidity Index, n (%)
  0–1 2467 (50.7) 6495 (44.6) <0.0001 1.8
  2–4 760 (15.6) 3502 (24.0)
  5–9 625 (12.8) 1783 (12.2)
  ≥10 1015 (20.9) 2792 (19.2)
mMRC score, n (%) n=4687 n=13676
  0–1 3361 (71.7) 9227 (67.5) <0.0001 11.1
  ≥2 1326 (28.3) 4449 (32.5)
GOLD groups (2017), n (%) n=4687 n=13676
  A 2867 (61.2) 7351 (53.8) <0.0001 17.7
  B 1121 (23.9) 3494 (25.5)
  C 494 (10.5) 1876 (13.7)
  D 205 (4.4) 955 (7.0)
FEV1 at index date
Mean (SD) absolute value (mL) 1762.5 (501.3) 1708.8 (496.3) <0.0001 10.8
Mean (SD) % predicted 67.5 (9.7) 66.0 (10.0) <0.0001 15.1
COPD exacerbations in year prior to index date, n (%)
  0 2907 (59.7) 7839 (53.8) <0.0001 16.5
  1 1256 (25.8) 3837 (26.3)
  2 472 (9.7) 1719 (11.8)
  3 147 (3.0) 710 (4.9)
  ≥4 85 (1.7) 467 (3.2)
  Mean (SD) 0.6 (1.0) 0.8 (1.1) <0.0001 16.5
COPD exacerbations in year prior to highest therapy initiation, n (%)
  0 3160 (64.9) 8027 (55.1) <0.0001 25.2
  1 1066 (21.9) 3504 (24.0)
  2 412 (8.5) 1667 (11.4)
  3 160 (3.3) 746 (5.1)
  ≥4 69 (1.4) 628 (4.3)
  Mean (SD) 0.6 (0.9) 0.8 (1.3) <0.0001 25.6
Continued
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(n=14572) P value sMd
COPD exacerbations, annual rate after initiation of highest therapy, rounded, n 
(%)
  0 3635 (74.7) 8822 (60.5) <0.0001 31.2
  1 946 (19.4) 4001 (27.5)
  2 196 (4.0) 1039 (7.1)
  3 55 (1.1) 369 (2.5)
  ≥4 35 (0.7) 341 (2.3)
  Mean (SD) 0.4 (0.7) 0.6 (1.0)
BMI, body mass index; ICS, inhaled corticosteroid; mMRC, modified Medical Research Council; P, p value for the Kruskal- Wallis equality- of- populations rank test, or the Pearson's 
chi- square test of independent categories, where appropriate; SMD, standardised mean difference.
Table 3 Continued
to long- acting bronchodilators was also associated with more 
decline (9.4 (95% CI 3.1 to 15.6), p=0.0035). See online 
supplementary figure S4 in online data supplementary.
dIsCussIon
This study is one of the first to examine the effect of COPD exac-
erbations on lung function decline taking into account the use of 
maintenance therapy and BEC. Our results suggest that an indi-
vidual with repeated exacerbations and a high BEC who is not 
on ICS therapy is subject to rapid lung function decline, which 
could be substantially reduced through ICS use. This novel and 
important observation addresses a very important need which is 
either not recognised or ignored and which has important poten-
tial consequences for patients with COPD.
Our results support the findings from post hoc analyses of the 
ISOLDE clinical trial in patients with more advanced COPD.19 
In these post hoc analyses, the rate of annual FEV1 decline 
was significantly reduced in patients on fluticasone propionate 
compared with placebo when blood eosinophil levels were ≥2%, 
but not when they were less than 2%. Our results highlight the 
importance of identifying patients who have COPD exacerba-
tions as well as a high level of blood eosinophils in daily clinical 
practice. This is key, as preventing exacerbations at an early stage 
could slow COPD progression and the risk of developing severe 
disease, and thus represents an important window of opportu-
nity for treatment. This approach is not considered in current 
treatment paradigms for COPD.
A few other studies have reported that increased exacerbations 
result in accelerated lung function decline in those with severe to 
moderate disease.9 11 More recently, accelerated decline in lung 
function following acute exacerbations (23 mL/year (95% CI 2 
to 44) per exacerbation) has been reported particularly in those 
with mild disease.12 The latter was however estimated from 
a relatively small number of patients with infrequent ICS use 
(13%). We confirm these findings in our study population of 
patients with mild to moderate airflow limitation.
An important conclusion from our study is that patients 
with a BEC of ≥350 cells/µL who continue to have exacerba-
tions under treatment with long- acting bronchodilators need 
additional treatment with ICS to prevent excess decline asso-
ciated with these exacerbations. A recently published observa-
tional study reported beneficial effects of prevalent ICS use on 
lung function decline, regardless of BEC using a cut- off point 
of ≥150 cells/µL.22 In addition, their results suggest that new 
ICS users with a high BEC may benefit more than those with 
a low BEC when first started on ICS. However, they did not 
consider the exacerbation rate occurring under maintenance 
therapy. Our findings are in line with current GOLD recom-
mendations (introduced in 2019 after our data collection) and 
provide further evidence to support the use of ICS therapy 
in patients with high BECs and a pattern of repeated exac-
erbations. It should be noted that in our study exacerbations 
were defined by the need for acute treatment, usually with 
OCS. Most randomised controlled trials use symptom- based 
algorithms which may catch different types of exacerbations, 
such as bouts of bronchitis, and these may be associated with 
lung function decline in a different way.23 However, validation 
work has shown that symptom codes in UK electronic medical 
records have a very low sensitivity for detecting acute exacer-
bations of COPD and most of the codes will probably overlap 
with OCS or antibiotics therapy.24
We have previously shown that elevated BECs are associated 
with increased exacerbation rates.25 Previous studies suggest 
that a higher BEC is associated with improved response to 
ICS- containing therapies in COPD patients with a history of 
exacerbations.3 26 Chronic eosinophilic inflammation has been 
associated with tissue remodelling and fibrosis in a number of 
chronic T- helper 2- mediated diseases, including asthma. This 
may manifest itself by occurrence of exacerbations, which may 
be triggered by external factors, such as a viral infection.27 Our 
results suggest that a high BEC is a useful marker of risk for 
more severe exacerbations in a substantial subset of the COPD 
population who also require ICS to reduce inflammation- 
driven tissue remodelling to prevent irreversible tissue damage 
and progression of disease. Low overall adherence to mainte-
nance therapy was associated with more lung function decline, 
further supporting the beneficial effects of maintenance 
therapy on lung function.
Within the group of patients treated with ICS- containing 
therapy in our study, no relevant impact of exacerbations 
occurring after initiation of ICS on decline was found in 
patients with a BEC ≥450 cells/µL. This provides evidence of 
a distinct phenotype associated with frequent exacerbations 
causing accelerated lung function decline when not treated 
with ICS.25
The strengths of our study include the large sample size, long 
follow- up and high number of spirometry measurements most 
patients underwent. To evaluate the impact of less accurate esti-
mates of lung function decline in patients with few measurements, 
we performed a sensitivity analysis excluding patients with less than 
five available measurements and found similar results. In 2017, 
three- quarters of patients with COPD in the UK general popula-
tion had FEV1 recorded. Repeated spirometry is recommended as 
standard COPD management in general practice in the UK within 
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Follow- up after index date, years
  Median (IQR) 6.1 (4.5–8.1) 6.0 (4.4–8.2) 5.9 (4.3–8.3) 0.8805 0.1 0.4
Age (years) at index date
  Mean (SD) 66.3 (10.5) 65.8 (9.9) 66.0 (9.7) 0.4996 4.6 1.9
Male sex, n (%) 187 (45.2) 4646 (49.6) 1487 (62.2) <0.0001 8.8 25.6
BMI, n (%)
  Underweight 28 (6.8) 263 (2.8) 61 (2.6) <0.0001 25.9 0.7
  Normal weight 166 (40.1) 2987 (31.9) 735 (30.7)
  Overweight 125 (30.2) 3365 (35.9) 918 (38.4)
  Obese 95 (22.9) 2757 (29.4) 678 (28.3)
Baseline smoking status, closest within 5 years, n (%) n=379 n=8787 n=2257
  Ex- smoker 189 (49.9) 4569 (52.0) 1198 (53.1) 0.4374 4.3 2.2
Smoking status up to 5 years of follow- up after index date, 
n (%)
n=392 n=8813 n=2230
  Sustained quitter 132 (33.7) 3190 (36.2) 839 (37.6) 0.2453 7.7 3.6
  Intermittent quitter 133 (33.9) 3096 (35.1) 784 (35.2)
  Continuous smoker 127 (32.4) 2527 (28.7) 607 (27.2)
Nasal polyps diagnosis ever, n (%) 3 (0.7) 73 (0.8) 62 (2.6) <0.0001 0.6 14.1
Osteoporosis diagnosis ever, n (%) 30 (7.2) 429 (4.6) 100 (4.2) 0.0225 11.3 1.9
Charlson Comorbidity Index, n (%)
  0–1 163 (39.4) 4108 (43.8) 961 (40.2) 0.0170 6.8 5.0
  2–4 96 (23.2) 1879 (20.0) 529 (22.1)
  5–9 51 (12.3) 1260 (13.4) 341 (14.3)
  ≥10 104 (25.1) 2125 (22.7) 561 (23.5)
mMRC score, n (%) n=396 n=9015 n=2294
  0–1 254 (64.1) 6165 (68.4) 1586 (69.1) 0.0080 14.4 3.0
  ≥2 142 (35.9) 2850 (31.6) 708 (30.9)
GOLD groups (2017), n (%) n=396 n=9015 n=2294
  A 201 (50.8) 5047 (56.0) 1252 (54.6) 0.0060 8.7 6.3
  B 114 (28.8) 2296 (25.5) 540 (23.5)
  C 53 (13.4) 1118 (12.4) 334 (14.6)
  D 28 (7.1) 554 (6.1) 168 (7.3)
FEV1 at index date
Mean (SD) absolute value (mL) 1651.1 (493.9) 1695.3 (491.4) 1781.9 (499.2) <0.0001 9.0 17.5
Mean (SD) % predicted 67.0 (10.1) 66.4 (9.9) 66.6 (9.8) 0.2266 6.6 2.7
COPD exacerbations in year prior to highest therapy 
initiation, n (%)
  0 263 (63.5) 5714 (61.0) 1352 (56.5) 0.0001 0.8 11.6
  1 83 (20.0) 2094 (22.3) 545 (22.8)
  2 36 (8.7) 921 (9.8) 269 (11.2)
  3 16 (3.9) 391 (4.2) 135 (5.6)
  ≥4 16 (3.9) 252 (2.7) 91 (3.8)
  Mean (SD) 0.7 (1.4) 0.7 (1.1) 0.8 (1.2) 0.0030 2.2 11.1
Cumulative daily dose of oral steroids in year prior to index 
date (mg /day), n (%)
n=100 n=2133 n=641
  No OCS 5 (5.0) 205 (9.6) 64 (10.0) <0.0001 41.8 0.8
  <2.5 72 (72.0) 1719 (80.6) 509 (79.4)
  2.5-<5 8 (8.0) 132 (6.2) 43 (6.7)
Continued
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  5–7.5 8 (8.0) 33 (1.5) 13 (2.0)
  ≥7.5 7 (7.0) 44 (2.1) 12 (1.9)
GP consultations, all- cause, number in year prior to index 
date, n (%)
  0–1 0 (0.0) 49 (0.5) 16 (0.7) 0.0189 21.0 0.9
  2–4 25 (6.0) 679 (7.2) 177 (7.4)
  5–8 63 (15.2) 1950 (20.8) 486 (20.3)
  9–13 110 (26.6) 2515 (26.8) 657 (27.5)
  14–17 59 (14.3) 1505 (16.1) 379 (15.8)
  18–22 66 (15.9) 1184 (12.6) 306 (12.8)
  23+ 91 (22.0) 1490 (15.9) 371 (15.5)
*As compared with the 50–349 cells/µL category.
†As compared with the 50–349 cells/µL category.
BMI, body mass index; GP, general practitioner; mMRC, modified Medical Research Council; P, p value for the Kruskal- Wallis equality- of- populations rank test, or the Pearson's 
chi- square test of independent categories, where appropriate; SMD, standardised mean difference.
Table 4 Continued
Figure 3 Impact of annual exacerbation rate on annual FEV1 decline 
following initiation of the highest level of therapy for patients receiving 
ICS and patients not receiving ICS. Error bars represent the 95% CI of 
the mean FEV1 decline. ICS, inhaled corticosteroid.
Figure 4 Impact of annual exacerbation rate on annual FEV1 decline 
in patients receiving ICS and patients not receiving ICS by blood 
eosinophil count. Error bars represent the 95% CI of the mean FEV1 
decline. (A) Blood eosinophil count <50 cells/µL. (B) Blood eosinophil 
count 50–349 cells/µL. (C) Blood eosinophil count ≥350 cells/µL.
the QOF.28 All available FEV1 values for patients were included 
in the analyses as we saw no reason to exclude values prior to the 
actual recording of a diagnosis, which may happen at any time over 
the course of COPD. A sensitivity analysis which excluded FEV1 
recordings prior to COPD diagnosis gave similar results (data not 
shown). A further strength of this study is that primary care data 
are used and thus the results are generalisable to the wider COPD 
population. Most studies that have assessed the role of BEC in the 
context of COPD are clinical trials. Finally, similar results were 
obtained when patients with a history of asthma were excluded 
from the analyses, showing no impact on the conclusions even if 
there was some misclassification between COPD and asthma.
Possible limitations of our study also need consideration. First, 
data in the OPCRD and CPRD are collected for clinical and routine 
use rather than specifically for research purposes. Quality control 
and validity checks of spirometry are conducted at the practice 
level with quality of spirometry undertaken in UK primary care 
generally high; however, the lack of standardisation across prac-
tices may have affected the accuracy of measurements.29 Also, it is 
unclear whether most of the spirometry measurements in our study 
were conducted pre- bronchodilator or post- bronchodilator, which 
may have resulted in some bias. It is recommended in the UK that 
diagnostic spirometry only be performed by an operator trained 
and assessed to the standards of the Association for Respiratory 
Technology and Physiology or equivalent, and that spirometry is 
carried out to the standards of the British Thoracic Society. This is 
to ensure delivery of high- quality diagnostic spirometry in primary 
care.30 Both data sources used for this study include dynamic popu-
lations of patients diagnosed with COPD. Follow- up time in the 
GP practice therefore varies between patients, mostly in an unbi-
ased way. We assumed that patients with ≥3 years of spirometry 
follow- up were representative of all patients with COPD whose 
disease was managed by a GP. This assumption is tenable because 
spirometry should be performed annually within the QOF, an incen-
tive programme for all GP practices in the UK to improve quality 
of care. However, it is unclear how the frequency with which FEV1 
measurements are taken is related to disease progression despite the 
precision of effect sizes in our models increasing with an increasing 
number of lung function measurements. Second, a reduction in 
exacerbation rate may be the underlying mechanism of action 
of ICS- containing therapies, and exacerbations occurring despite 
therapy may have different effects on lung function decline than 
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exacerbations that were prevented. It is also possible that patients 
on ICS receive better general care, visit their GP more often and 
have more spirometry readings; however, in our study, there were 
no relevant differences in GP consultations in the baseline year, 
neither for COPD- related nor for all- cause consultations, between 
ICS and non- ICS populations (online supplementary table S1). We 
were limited in our ability to model the effect of adherence (those 
doing worse are more likely to be adherent) and perhaps underesti-
mated the benefit of treatment with ICS. Another limitation is that 
information on the occurrence of hospital admissions for COPD 
exacerbation was based on GP records, which has been reported to 
have low sensitivity for detecting events in the CPRD.31 This may 
have caused some (non- differential) misclassification bias of the 
mean rate of COPD exacerbations over time. A further limitation 
is that in 1% of patients, the exacerbation rate had to be estimated 
over a short period of 6–12 months which may have underesti-
mated the exacerbation rate during total spirometry follow- up; 
however, it is unlikely that this significantly influenced the results. 
Also, BECs are not recorded routinely in general practice, which 
may have influenced the extent to which the study population is 
representative of the overall COPD population. In addition, BECs 
may vary over time and associations may have been different if this 
was taken into account.32 The blood eosinophil cut- off points used 
in our study were based on the recording of the original data and 
were not as defined in current GOLD recommendations; however, 
it is thought this would have minimal effect on the results. Finally, 
there is a possibility of residual confounding associated with the 
observational study design despite analyses being adjusted for well- 
known independent risk factors of lung function decline.
In conclusion, some patients with COPD experience progressive 
lung function decline. We have previously demonstrated that a high 
BEC is associated with a higher risk of exacerbations.25 Although 
firm conclusions cannot be drawn from our hypothesis- generating 
study, the results suggest that exacerbations in patients with eosin-
ophilic inflammation of the airways influence the progression of 
COPD especially when the patient is not on ICS. An individual 
with repeated exacerbations and a high BEC but not on ICS therapy 
may be subject to faster lung function decline. ICS- containing ther-
apies in these patients could attenuate lung function decline, but 
more research is needed to confirm this. We recommend a lung 
function assessment in patients aged >35 years with a high BEC 
and repeated prescriptions for oral steroids as ICS intervention in 
these cases may change the course of COPD at the early stages.
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